Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

588 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer prevention and the American Society of Clinical Oncology.
Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Kramer BS, Garber JE, Hawk E, Ganz PA, Somerfield MR; Writing Committee of the ASCO Cancer Prevention Committee. Lippman SM, et al. J Clin Oncol. 2004 Oct 1;22(19):3848-51. doi: 10.1200/JCO.2004.07.139. Epub 2004 Sep 7. J Clin Oncol. 2004. PMID: 15353541 No abstract available.
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology. Visvanathan K, et al. Among authors: lippman sm. J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470930 Free PMC article.
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM. Visvanathan K, et al. Among authors: lippman sm. J Clin Oncol. 2013 Aug 10;31(23):2942-62. doi: 10.1200/JCO.2013.49.3122. Epub 2013 Jul 8. J Clin Oncol. 2013. PMID: 23835710 Review.
Future cancer research priorities in the USA: a Lancet Oncology Commission.
Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Jaffee EM, et al. Among authors: lippman sm. Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208398 Free PMC article. Review.
Transforming Cancer Prevention through Precision Medicine and Immune-oncology.
Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM. Kensler TW, et al. Among authors: lippman sm. Cancer Prev Res (Phila). 2016 Jan;9(1):2-10. doi: 10.1158/1940-6207.CAPR-15-0406. Cancer Prev Res (Phila). 2016. PMID: 26744449 Free PMC article.
Cancer Prevention: Obstacles, Challenges and the Road Ahead.
Meyskens FL Jr, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS. Meyskens FL Jr, et al. Among authors: lippman sm. J Natl Cancer Inst. 2015 Nov 7;108(2):djv309. doi: 10.1093/jnci/djv309. Print 2016 Feb. J Natl Cancer Inst. 2015. PMID: 26547931 Free PMC article. Review.
588 results